A recent large multinational study demonstrated that monoallelic pathogenic PALB2 germline variants predispose to female and male breast cancers with relative risks above 7, and by the age of 80 years 53% (CI 95%: 44–63%) of the female mutation carriers are predicted to develop the malignancy [3]. The gene discussed is PALB2; the disease is breast cancer.